secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001193125-24-193404
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon initiates Phase 3 ARCHER II GA trial; Phase 2 data show vision protection
--------------------------------------------------------------------------------

- Dosing started in global pivotal Phase 3 ARCHER II trial of ANX007 for geographic atrophy (GA).
- Topline data expected in second half of 2026; trial to enroll ~630 patients.
- Phase 2 ARCHER: ANX007 reduced ≥15-letter BCVA loss to 5.6% vs sham 21.3% (p=0.0021).
- Structural protection: up to 60% photoreceptor preservation in central fovea (p=0.0319).
- FDA/EMA aligned on BCVA as primary endpoint; EU PRIME and US Fast Track designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524193404/0001193125-24-193404-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312524193404/d833325d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-193404

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer